[1] Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Medical Sciences. 2021;9(1):3. https://doi.org/10.3390/medsci9010003.
[2] Heider M, Nickel K, Högner M, Bassermann F. Multiple myeloma: molecular pathogenesis and disease evolution. Oncology Research and Treatment. 2021;44(12):672-81. https://doi.org/10.1159/000520312.
[3] Jaffe R. WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, editor. Lyon, France: International agency for research on cancer; 2008;358-60.
[4] Greer JP, Arber DA, Glader B, List AF, Means RT, Paraskevas F, et al. Wintrobe's clinical hematology. Lippincott Williams & Wilkins; 2013.
[5] Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA oncology. 2018;4(9):1221-7. https://doi.org/10.1001/jamaoncol.2018.2128.
[8] Kalita LK, Kalita C, Gogoi PK, Sarma UC. A clinicoepidemiological study of multiple myeloma− a hospital based study at Gauhati Medical College and Hospital, Guwahati, Assam. J Evid Based Med Health. 2016;3(36):1788-94. https://doi.org/10.18410/jebmh/2016/400.
[9] Nandakumar A. National Cancer Registry Programme. Consolidated Report of the Population Based Cancer Registries. Incidence and Distribution of Cancer: 1990–96. Indian Council of Medical Research, New Delhi. Cancer. 2019;125:3184-97.
[10] Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. Journal of clinical oncology. 2005;23(15):3412-20. https://doi.org/10.1200/JCO.2005.04.242.
[11] Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. Journal of clinical oncology. 2015;33(26):2863-9. https://doi.org/10.1200/JCO.2015.61.2267.
[12] Pegu AK, Dutta A, Todi VK. Clinical profile of multiple myeloma in a tertiary care center from North East India. Cough. 2016;5(52):3382-85. https://doi.org/10.14260/jemds/2016/781.
[13] Sharma S, Suri J, Kour B. Clinicopathological study of spectrum of plasma cell dyscrasias in a tertiary care centre-retrospective four year study. Indian Journal of Pathology and Oncology. 2020;7(1):158-63. https://doi.org/10.18231/j.ijpo.2020.030.
[14] Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. InMayo Clinic Proceedings 2003;78(1):21-33. https://doi.org/10.4065/78.1.21.
[15] Sultan S, Irfan SM, Parveen S, Ali H, Basharat M. Multiple Myeloma: A retrospective analysis of 61 patients from a tertiary care center. Asian Pacific Journal of Cancer Prevention. 2016;17(4):1833-5. http://dx.doi.org/10.7314/APJCP.2016.17.4.1833.
[16] Mishra D, Meena G, Gandhi S, Prasad K. A study of clinical profile and laboratory parameters in multiple myeloma at SMS Medical College & Hospital, Jaipur. Paripex Ind J of Research. 2021;10(10):11-14. https://doi.org/10.36106/paripex/8507378.
[17] Shin J, Koh Y, Youk J, Kim M, Kim BS, Choi CW, et al. Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications. The Korean journal of internal medicine. 2017;32(4):722-30. https://doi.org/10.3904/kjim.2016.256.
[18] Jakhetia H. Clinicopathologic profile in Multiple Myeloma: A case series of 30 cases. Journal of Advanced Medical and Dental Sciences Research. 2019;7(9):142-7.
[19] Kaushik R, Thakur RK, Gulati A, Sharma SK. Multiple myeloma: clinico-hematological profile in a tertiary care hospital: a three years study. Annals of Pathology and Laboratory Medicine. 2017;4(5):270-5.
[20] Sheik N, Variganji SK, Inugati VR. Clinico-hematological profile of multiple myeloma in a teaching hospital-a 2 year study. IP Arch Cytol Histopathol Res. 2019;4(04):305-9.